Is cervical cancer vaccine available for HPV infection?

Cervical cancer vaccination can still be given after HPV infection. The HPV vaccine can prevent uninfected HPV subtypes. Although it has no therapeutic effect on infected subtypes, it can reduce the risk of other high-risk HPV infections. It is recommended to evaluate the timing of vaccination under the guidance of a doctor.

The HPV vaccine mainly provides preventive protection against high-risk HPV viruses, such as types 16, 18, etc. Even if you are infected with one HPV subtype, the vaccine can still protect against infection with other subtypes. For example, after being infected with HPV type 16, vaccination with the nine-valent vaccine can still protect against the other eight subtypes including type 31 and type 33. The vaccine stimulates the body to produce antibodies that block the virus from invading cervical cells, thereby reducing the risk of persistent infection and cancer. Regular cervical cancer screening is required after vaccination, as the vaccine cannot clear existing infections.

Vaccination may need to be postponed under certain circumstances, such as pregnancy, acute febrile illness, or allergies to vaccine components. People with low immune function may affect the antibody production effect. If high-grade cervical lesions have been diagnosed, priority should be given to completing treatment before evaluating the necessity of vaccination. Before vaccination, the infection status needs to be confirmed through HPV typing testing, and the doctor will adjust the vaccination plan according to individual circumstances.

After vaccination, you still need to maintain a healthy lifestyle, including regular work and rest, a balanced diet and safe sexual behavior. It is recommended that women over 30 years old undergo combined HPV testing and TCT examination every 3-5 years. Early detection of cervical lesions can significantly improve the cure rate. Avoiding risk factors such as smoking and long-term oral contraceptives can help reduce the probability of cervical cancer.